DK2902031T3 - Topically active steroid for use in radiation damage - Google Patents

Topically active steroid for use in radiation damage Download PDF

Info

Publication number
DK2902031T3
DK2902031T3 DK15158919.9T DK15158919T DK2902031T3 DK 2902031 T3 DK2902031 T3 DK 2902031T3 DK 15158919 T DK15158919 T DK 15158919T DK 2902031 T3 DK2902031 T3 DK 2902031T3
Authority
DK
Denmark
Prior art keywords
radiation
tbi
damage
kgf
bdp
Prior art date
Application number
DK15158919.9T
Other languages
Danish (da)
English (en)
Inventor
George B Mcdonald
Robert N Brey
Christopher Schaber
Original Assignee
Soligenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soligenix Inc filed Critical Soligenix Inc
Application granted granted Critical
Publication of DK2902031T3 publication Critical patent/DK2902031T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DK15158919.9T 2008-12-08 2009-12-08 Topically active steroid for use in radiation damage DK2902031T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12078508P 2008-12-08 2008-12-08
EP09836727.9A EP2373160B1 (en) 2008-12-08 2009-12-08 Topically active steroids for use in radiation injury

Publications (1)

Publication Number Publication Date
DK2902031T3 true DK2902031T3 (en) 2019-01-14

Family

ID=42310112

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15158919.9T DK2902031T3 (en) 2008-12-08 2009-12-08 Topically active steroid for use in radiation damage
DK09836727.9T DK2373160T3 (en) 2008-12-08 2009-12-08 TOPIC ACTIVE STEROIDS FOR USE IN RADIATION

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09836727.9T DK2373160T3 (en) 2008-12-08 2009-12-08 TOPIC ACTIVE STEROIDS FOR USE IN RADIATION

Country Status (12)

Country Link
US (3) US20100183749A1 (enExample)
EP (2) EP2373160B1 (enExample)
JP (2) JP5709266B2 (enExample)
KR (2) KR101783577B1 (enExample)
CN (2) CN102307466A (enExample)
AU (1) AU2009333538B2 (enExample)
CA (1) CA2745930C (enExample)
DK (2) DK2902031T3 (enExample)
IL (1) IL213411A (enExample)
NZ (1) NZ593694A (enExample)
SG (2) SG10201704531XA (enExample)
WO (1) WO2010077681A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010054321A2 (en) 2008-11-07 2010-05-14 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US8642339B2 (en) 2009-02-03 2014-02-04 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
WO2011059586A2 (en) 2009-10-30 2011-05-19 The Regents Of The University Of Michigan Multifunctional small molecules
US9381187B2 (en) * 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
US9402911B2 (en) 2011-12-08 2016-08-02 The Regents Of The University Of Michigan Multifunctional small molecules
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
US20160074400A1 (en) * 2012-08-06 2016-03-17 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
WO2014059068A1 (en) * 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Methods for the treatment and prevention of osteoporosis and bone-related disorders
WO2014134038A1 (en) * 2013-02-28 2014-09-04 The Regents Of The University Of Michigan Compositions and methods relating to induction of intestinal stem cell homeogenesis and/or regeneration
CA2923553C (en) 2013-09-13 2023-05-23 Soligenix, Inc. Novel peptides and analogs for use in the treatment of oral mucositis
US11311598B2 (en) 2013-09-13 2022-04-26 Soligenix, Inc. Peptides and analogs for use in the treatment of oral mucositis
US9439947B2 (en) 2014-03-28 2016-09-13 Albert Einstein College Of Medicine, Inc. Therapy for radiation-induced lung injury
CN114306208A (zh) * 2014-10-02 2022-04-12 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗的用途
WO2017011457A1 (en) * 2015-07-12 2017-01-19 The University Of Tennessee Research Foundation Compositions and methods for protecting colonic epithelial barrier function
WO2017119988A2 (en) * 2015-12-10 2017-07-13 Memorial Sloan Kettering Cancer Center Radioprotection by wnt activation
CN107753932A (zh) * 2016-08-22 2018-03-06 中国辐射防护研究院 Kgf在制备治疗或预防放射性肠炎药物中的用途
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
AU6232899A (en) * 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
US20020086857A1 (en) * 2000-09-15 2002-07-04 Mcdonald George B. Method of long-term treatment of graft-versus-host disease using topical active corticosterioids
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
AU2002254205B2 (en) * 2001-03-15 2007-05-10 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
CN102218070A (zh) * 2004-12-30 2011-10-19 索利吉尼克斯公司 用二丙酸倍氯米松和泼尼松治疗移植物抗宿主病和白血病
JP4839436B2 (ja) * 2005-11-02 2011-12-21 国立大学法人徳島大学 消化管粘膜保護剤、カベオリン遺伝子発現促進剤及び抗ストレス剤
US20070293458A1 (en) 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
US20080233088A1 (en) * 2007-02-16 2008-09-25 Varian Medical Systems Technologies, Inc. Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation
DK3354276T3 (da) * 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation

Also Published As

Publication number Publication date
US20100183749A1 (en) 2010-07-22
WO2010077681A1 (en) 2010-07-08
KR20170001735A (ko) 2017-01-04
CA2745930C (en) 2017-05-02
EP2373160A1 (en) 2011-10-12
EP2373160B1 (en) 2017-10-25
AU2009333538B2 (en) 2014-09-11
SG10201704531XA (en) 2017-07-28
US20200155571A1 (en) 2020-05-21
EP2902031A1 (en) 2015-08-05
CN102307466A (zh) 2012-01-04
HK1207582A1 (en) 2016-02-05
EP2373160A4 (en) 2012-06-13
US20170333448A1 (en) 2017-11-23
IL213411A (en) 2016-12-29
CA2745930A1 (en) 2010-07-08
JP2012511034A (ja) 2012-05-17
CN106692162A (zh) 2017-05-24
NZ593694A (en) 2013-09-27
KR101783577B1 (ko) 2017-09-29
EP2902031B1 (en) 2018-10-24
JP5905562B2 (ja) 2016-04-20
DK2373160T3 (en) 2018-01-02
AU2009333538A1 (en) 2011-07-14
KR20110092351A (ko) 2011-08-17
JP5709266B2 (ja) 2015-04-30
SG171997A1 (en) 2011-07-28
JP2015038155A (ja) 2015-02-26
IL213411A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
EP2902031B1 (en) Topically active steroid for use in radiation injury
US20050163764A1 (en) Treatment with agonists of toll-like receptors
BRPI0706379A2 (pt) tratamento de hepatite viral
Sun et al. Dehydrocostus lactone alleviates irinotecan-induced intestinal mucositis by blocking TLR4/MD2 complex formation
KR101628448B1 (ko) 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법
WO2020163833A2 (en) Growth hormone-releasing hormone antagonists and uses thereof
WO2013192367A1 (en) Neuroendocrine tumor treatment
HK1207582B (en) Topically active steroid for use in radiation injury
HK1162861A (en) Topically active steroids for use in radiation injury
HK1162861B (en) Topically active steroids for use in radiation injury
EP1827476B1 (en) Use of bombesin/gastrin-releasing peptide antagonist for the treatment of sepsis, septic shock, acute lung injury or rheumatoid arthritis
EP1830857B1 (en) Beclomethasone dipropionate and prednisone for reducing mortality associated with graft-versus-host disease
KR20210126515A (ko) 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
US20190358300A1 (en) Method and composition for novel use of igf-1 and garcinol to induce clinical weight loss
CN108379557A (zh) 使用白介素因子-37治疗特发性肺纤维化
CN121371149A (zh) 基于Tim-4功能结构域的巨噬细胞靶向纳米材料联合生物制剂在炎症性肠病中的应用
EP1660008A2 (en) Therapeutic use of g53135-05(fgf-20) in radiation protection
Hayashi et al. Lubiprostone Prevents NSAID-Induced Small Intestinal Damage by Suppression of Inflammatory Mediators' Expression via EP4 Receptors
JP2002524481A (ja) 他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置